Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/10795/000001079518000036/bdx2018-09x3010xk.htm
August 2022
August 2022
August 2022
May 2022
May 2022
April 2022
April 2022
April 2022
March 2022
March 2022
• | As reported, full fiscal year revenues of $15.983 billion increased 32.2 percent. |
• | On a comparable, currency-neutral basis, revenues increased 5.8 percent for the full fiscal year. |
• | As reported, full fiscal year diluted earnings per share of $0.60 decreased 87.0 percent. |
• | As adjusted, full fiscal year diluted earnings per share of $11.01 increased 16.1 percent, or 12.3 percent on a currency-neutral basis. |
• | The company expects full fiscal year 2019 revenues to increase 8.5 to 9.5 percent as reported, or 5.0 to 6.0 percent on a comparable, currency-neutral basis. |
• | As adjusted, the company expects full fiscal year 2019 diluted earnings per share to be between $12.05 and $12.15, resulting in growth of approximately 13.0 to 14.0 percent on a currency-neutral basis, which includes an adverse impact of approximately 600 basis points related to headwinds and divestitures. This represents growth of approximately 10.0 percent including the estimated unfavorable impact of foreign currency. |
• | Fiscal 2019 earnings per share expectations include high-single digit accretion from the C. R. Bard acquisition. |
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/10795/000001079518000036/bdx2018-09x3010xk.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Becton Dickinson Co.
Becton Dickinson Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:
Rating
Learn More![]()
Weakness in the global economy and financial markets, which could increase the cost of operating our business, weaken demand for our products and services, negatively impact the prices we can charge for our products and services, or impair our ability to produce our products.
BDs effective tax rate in any given period could be impacted if, upon resolution with taxing authorities, we prevailed in positions for which reserves have been established, or we were required to pay amounts in excess of established reserves.
BD management operates the business consistent with the following core strategies: To increase revenue growth by focusing on our core products, services and solutions that deliver greater benefits to patients, healthcare workers and researchers; To supplement our internal growth through strategic acquisitions; To continue investment in research and development for platform extensions and innovative new products; To make investments in growing our operations in emerging markets; To improve operating effectiveness and balance sheet productivity; To drive an efficient capital structure and strong shareholder returns.
Selling and administrative expense as a percentage of revenues in 2018 was lower compared with 2017 which primarily reflected a reduction in the general and administrative costs allocated to the segment, as noted above.
Pending and potential future litigation or other proceedings asserting, and/or subpoenas seeking information with respect to, alleged violations of law (including in connection with federal and/or state healthcare programs (such as Medicare or Medicaid) and/or sales and marketing practices (such as investigative subpoenas and the civil investigative demands received by BD and Bard)), antitrust claims, product liability (which may involve lawsuits seeking class action status or seeking to establish multi-district litigation proceedings, including claims relating to our hernia repair implant products, surgical continence products for women and vena cava filter products), claims with respect to environmental matters, and patent infringement, and the availability or collectability of insurance relating to any such claims.
The Medical segment's gross profit...Read more
Revenue growth in the Medication...Read more
The fiscal year 2018 change...Read more
The increase in interest expense...Read more
The decrease in interest income...Read more
The operating performance impacts in...Read more
The increase in interest income...Read more
Emerging market revenue growth in...Read more
Medical segment growth in 2018...Read more
The impact of business combinations...Read more
Emerging market revenue growth in...Read more
Expected return on plan assets...Read more
These unfavorable impacts to the...Read more
Research and development expense as...Read more
The Medical segment's operating income...Read more
The effect of market fluctuations...Read more
The impact that changes in...Read more
We used $230 million of...Read more
We determine the fair value...Read more
The Medical segment's underlying revenue...Read more
We selectively use financial instruments...Read more
Our strategy focuses on four...Read more
We used proceeds from this...Read more
We will use a long-term...Read more
Forward-looking statements may be identified...Read more
In determining whether a valuation...Read more
Volume growth in 2018 attributable...Read more
International revenue growth in 2017...Read more
Foreign currency translation favorably impacted...Read more
The Life Sciences segment's 2018...Read more
Security breaches of our information...Read more
BD and its representatives may...Read more
Environmental laws, particularly with respect...Read more
Our corporate credit ratings with...Read more
The Interventional segment's operating income...Read more
Substantially all of the integration...Read more
Underlying 2018 revenue growth in...Read more
Management believes the following critical...Read more
The decrease in the effective...Read more
The Company had no commercial...Read more
Deficit reduction efforts or other...Read more
Net cash flows from investing...Read more
Intangible assets with finite lives,...Read more
Revenue growth in the Diagnostic...Read more
Medical segment revenue growth in...Read more
The segment?s 2017 revenue growth...Read more
Underlying growth was particularly driven...Read more
BD and its subsidiaries transact...Read more
Also in May 2017, we...Read more
Our standalone software application sales...Read more
Reflected in the financial results...Read more
As a result of the...Read more
There were no borrowings outstanding...Read more
We also consider trends related...Read more
The Medical segment?s underlying growth...Read more
Revenue growth in 2017 also...Read more
Growth in the Preanalytical Systems...Read more
The foregoing list sets forth...Read more
In addition, pricing pressure exists...Read more
Delays in obtaining necessary approvals...Read more
International revenues in 2018 benefited...Read more
The increase in interest expense...Read more
Our ability to sustain our...Read more
The following summarizes Life Sciences...Read more
International revenue growth in 2017...Read more
These impacts to U.S. revenues...Read more
To determine the expected long-term...Read more
We may, from time to...Read more
Borrowings outstanding under the new,...Read more
BD?s worldwide revenues by geography...Read more
The revenue allocated to extended...Read more
The product?s software elements must...Read more
Our financial position remains strong,...Read more
Competitive factors that could adversely...Read more
All statements that address our...Read more
Worldwide revenues in 2018 of...Read more
The estimates and assumptions used...Read more
Management?s best estimate of selling...Read more
These benefit costs include assumptions...Read more
When applying the relative selling...Read more
We believe our discount rate...Read more
Risks relating to our acquisition...Read more
The effect of adverse media...Read more
We have historically asserted indefinite...Read more
The final impact of the...Read more
Spending in 2018, 2017 and...Read more
While the economic environment for...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
Becton Dickinson Co provided additional information to their SEC Filing as exhibits
Ticker: BDX
CIK: 10795
Form Type: 10-K Annual Report
Accession Number: 0000010795-18-000036
Submitted to the SEC: Wed Nov 21 2018 10:34:32 AM EST
Accepted by the SEC: Wed Nov 21 2018
Period: Sunday, September 30, 2018
Industry: Surgical And Medical Instruments And Apparatus